In recent months, vaccine stocks have been among the most heavily traded companies on the stock market. Over $250 billion is what Moderna and Biontech are currently worth. Biontech’s performance since its IPO in 2019 has been 2,440%.
But this week Biontech had to give up some gains on the stock markets. Concerns about certain rare side effects following vaccinations against COVID-19 weighed heavily on shares of mRNA vaccine makers Moderna and Biontech in U.S. trading Wednesday. Currently, Biontech is trading about 18 percent below its all-time high.
But Biontech may soon be much more than Corona vaccine. With its mRNA technology, the company could achieve a breakthrough in the fight against malaria and even cancer.
Diese Website verwendet Cookies. Notwendige Cookies sind für die Funktionalität unserer Website erforderlich, optionale Cookies setzen wir nur mit Ihrer Genehmigung. Weitere Informationen finden Sie in unserer Datenschutzerklärung und unter Einstellungen.